ArticleBMC cancer2016
Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.
Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- High Prevalence of Acquired Platelet Secretion Defects in Multiple Myeloma.Hamostaseologie · 2026Article
- Early mortality in multiple myeloma patients with renal impairment: a nested case-control study.BMC nephrology · 2026Article
- Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.International journal of hematology · 2026Article
- Development and validation of a novel frailty model for the patients with newly diagnosed multiple myeloma.European journal of medical research · 2025Article
- Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram.Biomedicines · 2025Article
- Article
- A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.Cancer · 2023Article
- Eastern Cooperative Oncology Group,Frontiers in microbiology · 2023Article
- Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).British journal of haematology · 2022Article
- IntestinalCancers · 2022Article
- Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen.Blood research · 2022Article
- Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study.Blood cancer journal · 2021Article
- [A predictive model based on risk factors for early mortality in patients with newly diagnosed multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Prognostic impact ofInternational journal of hematology · 2021Article
- Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.European journal of haematology · 2019Article
- Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice.The Journal of international medical research · 2018Article
- Polymorphisms in the promoter region of theOncotarget · 2018Article
- Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients.
methodsRetrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed.
resultsThe median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m(2)), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001).
conclusionsIn conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.